Company’s 36-month beta value is -0.50.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for SMMT is 115.12M, and currently, short sellers hold a 18.79% ratio of that floaft. The average trading volume of SMMT on March 19, 2025 was 2.52M shares.
SMMT) stock’s latest price update
Summit Therapeutics Inc (NASDAQ: SMMT)’s stock price has gone decline by -1.49 in comparison to its previous close of 20.13, however, the company has experienced a 7.19% increase in its stock price over the last five trading days. businesswire.com reported 2025-03-17 that MIAMI–(BUSINESS WIRE)—- $SMMT–Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced that Robert LaCaze has joined Summit Therapeutics as Chief Commercial Officer, reporting to Manmeet S. Soni, Chief Operating Officer and Chief Financial Officer, effective immediately. Robert W. Duggan and Dr. Maky Zanganeh, Co-CEOs of Summit Therapeutics, stated, “Robert’s extensive experience and proven track record in the oncology space make him an exceptional addition to our te.
SMMT’s Market Performance
SMMT’s stock has risen by 7.19% in the past week, with a monthly drop of -7.21% and a quarterly rise of 10.97%. The volatility ratio for the week is 7.28% while the volatility levels for the last 30 days are 8.66% for Summit Therapeutics Inc The simple moving average for the past 20 days is 1.15% for SMMT’s stock, with a 19.10% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with Evercore ISI repeating the rating for SMMT by listing it as a “Outperform.” The predicted price for SMMT in the upcoming period, according to Evercore ISI is $30 based on the research report published on March 12, 2025 of the current year 2025.
Goldman, on the other hand, stated in their research note that they expect to see SMMT reach a price target of $42. The rating they have provided for SMMT stocks is “Buy” according to the report published on February 28th, 2025.
Truist gave a rating of “Buy” to SMMT, setting the target price at $35 in the report published on January 08th of the current year.
SMMT Trading at -1.34% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -41.49% of loss for the given period.
Volatility was left at 8.66%, however, over the last 30 days, the volatility rate increased by 7.28%, as shares sank -5.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +8.07% upper at present.
During the last 5 trading sessions, SMMT rose by +7.19%, which changed the moving average for the period of 200-days by +575.64% in comparison to the 20-day moving average, which settled at $19.60. In addition, Summit Therapeutics Inc saw 11.12% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 54,321 shares at the price of $3.72 back on Mar 27 ’24. After this action, Zanganeh Mahkam now owns 24,923,800 shares of Summit Therapeutics Inc, valued at $201,874 using the latest closing price.
Zanganeh Mahkam, the Chief Executive Officer of Summit Therapeutics Inc, purchase 30,000 shares at $3.75 during a trade that took place back on Mar 26 ’24, which means that Zanganeh Mahkam is holding 30,000 shares at $112,500 based on the most recent closing price.
Stock Fundamentals for SMMT
The total capital return value is set at -0.54. Equity return is now at value -94.89, with -69.32 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at -19.69. The debt to equity ratio resting at 0.02. The interest coverage ratio of the stock is -24.28.
Currently, EBITDA for the company is 0.31 million with net debt to EBITDA at 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.15.
Conclusion
In a nutshell, Summit Therapeutics Inc (SMMT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
